

### **Amendments to Claims**

#### **In the Claims:**

Prior to further examination of this application, please amend the claims as shown below.

1. *(Canceled)*
2. *(Currently amended)* The RNAi molecule of claim ~~41~~ that is a single stranded siRNA that forms a hairpin structure.
3. *(Currently amended)* The RNAi molecule of claim ~~41~~ that is a double stranded siRNA.
4. *(Currently amended)* An interfering RNA (RNAi) molecule that comprises~~The RNAi molecule of claim 1 that (i) comprises, or (ii) hybridizes to a Met target sequence that comprises, a sequence selected from the group consisting of: (a) SEQ ID NO:9; (b) SEQ ID NO:10; (c) SEQ ID NO:11; (d) SEQ ID NO:12; (e) SEQ ID NO:13; (f) SEQ ID NO:14; (g) SEQ ID NO:15; (h) SEQ ID NO:16; (i) SEQ ID NO:17; and (j) SEQ ID NO:18.~~
- 5-7. *(Canceled)*
8. *(Currently amended)* A DNA molecule encoding the RNAi molecule of claim ~~41~~.
9. *(Currently Amended)* An expression construct comprising DNA that encodes the RNAi molecule of claim ~~41~~ operatively linked to a promoter that drives the expression of said RNAi

molecule in a *c-met*-expressing cell.

10. (*Original*) An expression construct comprising the DNA molecule of claim 8.
11. (*Currently Amended*) The expression construct of claim 9, wherein a promoter is one that drives the expression of said RNAi molecule in a *c-met*-expressing tumor or cancer cell.
12. (*Previously presented*) The expression construct of claim 11 wherein the promoter is a polIII promoter.
13. (*Original*) The expression construct of claim 12 wherein the polIII promoter is a U6 promoter.
14. (*Previously presented*) A viral vector comprising the expression construct of claim 9.
15. (*Original*) The viral vector of claim 14 that is a transient expression vector.
16. (*Currently amended*) The viral vector of claim 14 ~~13~~ that is a stable expression vector.
17. (*Previously presented*) The viral vector of claim 14 that is an adenoviral vector.
18. (*Original*) The adenoviral vector of claim 17 that is an Ad5 viral vector.

Applicant : Nariyoshi Shinomiya et al.  
Appln. No. : 10/599,327  
Page : 4

19. (*Original*) The Ad5 viral vector of claim 18 selected from the group consisting of: (a) si-mMet-Ad5<sup>57</sup>; (b) si-mMet-Ad5<sup>60</sup>; (c) si-mMet-Ad5<sup>110</sup>; (d) si-mMet-Ad5<sup>178</sup>; (e) si-hMet-Ad5<sup>16</sup>; (f) si-hMet-Ad5<sup>62</sup>; (g) si-hMet-Ad5<sup>221</sup>; (h) si-dMet-Ad5<sup>111</sup>; (i) si-dMet-Ad5<sup>197</sup>; and (j) si-dMet-Ad5<sup>223</sup>.

20. (*Original*) The Ad5 viral vector of claim 19 wherein the vector is si-hMet-Ad5<sup>16</sup>, si-hMet-Ad5<sup>62</sup>; or si-hMet-Ad5<sup>221</sup>.

21-37. (*Canceled*)

38. (*Previously presented*) A method of treating a c-met<sup>+</sup> tumor or cancer in a subject, comprising administering to the subject by an effective route, an amount of the viral vector of claim 14 effective for inhibiting expression of c-met and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said tumor or cancer cells.

39-47. (*Canceled*)

48. (*Previously presented*) The method of claim 38 wherein the tumor or cancer is glioblastoma, prostate or gastric.

49. (*Previously presented*) A method of treating a c-met<sup>+</sup> tumor or cancer in a subject,

Applicant : Nariyoshi Shinomiya et al.  
Appln. No. : 10/599,327  
Page : 5

comprising administering to the subject by an effective route, an amount of the viral vector of claim 19 effective for inhibiting expression of *c-met* and thereby (i) inhibiting the growth, invasion or metastasis of cells of said tumor or cancer, or (ii) killing said tumor or cancer cells.

50. (*Previously presented*) The method of claim 49 wherein the tumor or cancer is glioblastoma, prostate or gastric.